Other Clinical Trial - The Benefit of Minocycline on Negative Symptoms in

Status Completed

Clinical Trial Summary

The purpose of this study is to investigate if minocycline limits the development of negative symptoms in early psychosis and to test via what mechanism of action this change occurs.

Clinical Trial Description

Background

Negative symptoms of psychosis do not respond to the traditional therapy with first- or second-generation antipsychotics and are among main causes of a decrease in quality of life observed in individuals suffering from the disorder. Minocycline, a broad-spectrum tetracyclic antibiotic displaying neuroprotective properties has been suggested as a new potential therapy for negative symptoms. In the two previous clinical trials comparing minocycline and placebo, both added to the standard care, patients receiving minocycline showed increased reduction in negative symptoms. Three routes to neuroprotection by minocycline have been identified: neuroprotection against grey matter loss, anti-inflammatory action and stabilisation of glutamate receptors. However, it is not yet certain what the extent of the benefit of minocycline in psychosis is and what its mechanism is. This proposal is for a multi-centre double-blind randomised placebo-controlled clinical trial entitled The Benefit of Minocycline on Negative Symptoms of Psychosis: Extent and Mechanism (BeneMin).

Methods

After providing informed consent, 226 participants in the early phase of psychosis will be randomised to receive either 100 mg modified-release capsules of minocycline or similar capsules with placebo for 12 months in addition to standard care. The participants will be tested for outcome variables before and after the intervention period. The extent of benefit will be tested via clinical outcome measures, namely the Positive and Negative Syndrome Scale score, social and cognitive functioning scores, antipsychotic medication dose equivalent and level of weight gain. The mechanism of action of minocycline will be tested via blood screening for circulating cytokines and magnetic resonance imaging with three-dimensional T1-weighted rapid gradient-echo, proton density T2-weighted dual echo and T2*-weighted gradient echo planar imaging with N-back task and resting state. Eight research centres in the United Kingdom (UK) and 15 National Health Service Trusts and Health Boards will be involved in recruiting participants, performing the study and analysing the data. ;

Study Design

Related Conditions & MeSH terms

Schizophrenia
Schizophrenia and Disorders With Psychotic Features
Schizophrenia Spectrum and Other Psychotic Disorders

Clinical Trial Details

NCT number	NCT02928965
Study type	Interventional
Source	University of Manchester
Contact
Status	Completed
Phase	Phase 2
Start date	February 2013
Completion date	May 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01196858` - Duration of Untreated Psychosis (DUP) and Pathways to Care in Nordland	N/A
Completed	`NCT00136760` - Contingent Incentives Plus Bupropion for Smoking in People With Schizophrenia	Phase 2
Completed	`NCT03309475` - Effectiveness of a Mindfulness-based Group Training Addressing Social Cognition in First Episode Psychosis (AGES-Mind)	N/A
Not yet recruiting	`NCT01968161` - Investigator Initiated Study - Asenapine Early Psychosis	Phase 4
Completed	`NCT00135772` - Nicotine and Cotinine Levels in Smokers With Schizophrenia and Schizoaffective Disorder - 2	N/A
Completed	`NCT02308462` - Implementation and Evaluation of a Family-based Intervention Program for Children of Mentally Ill Parents	N/A
Completed	`NCT03133143` - Video Games Among People With Schizophrenia	N/A
Completed	`NCT00309452` - Specialized Treatment Early in Psychosis (STEP)	N/A
Not yet recruiting	`NCT02240173` - Antipsychotic Effects of Sorghum Bicolor (JOBELYN) in the Treatment of Schizophrenia	Phase 1/Phase 2
Completed	`NCT00218218` - Effects of Transdermal Nicotine on Smoking, Craving and Withdrawal in People With Schizophrenia	Phase 2
Completed	`NCT02321943` - Anomalous Self-Experience in First Episode Psychosis - A Six-Year Follow-Up Study	N/A
Completed	`NCT02307396` - Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients	Phase 4
Terminated	`NCT00748566` - One-Year Trial Of Oral Ziprasidone In Patients With Metabolic Syndrome	Phase 4
Recruiting	`NCT00791882` - Social Skills Training in Refractory Schizophrenia	N/A
Completed	`NCT00363181` - Side Effects of Antipsychotic Medications
Completed	`NCT00137189` - Resource-oriented Music Therapy for Psychiatric Patients With Low Therapy Motivation	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

The Benefit of Minocycline on Negative Symptoms in Schizophrenia: Extent and Mechanisms — BeneMin

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms